Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Rosuvastatin in African Americans With Cerebrovascular Disease (RIAA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01975194
Recruitment Status : Terminated (loss of research personnel)
First Posted : November 3, 2013
Last Update Posted : November 5, 2013
Information provided by (Responsible Party):
Seemant Chaturvedi, Wayne State University

Brief Summary:
This study will assess the rate at which rosuvastatin will achieve LDL targets in African American patients with previous history of stroke or TIA.

Condition or disease Intervention/treatment Phase
Stroke Transient Ischemic Attack Drug: Rosuvastatin Phase 4

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Use of Rosuvastatin to Achieve Lipid Targets in African American Subjects With Cerebrovascular Disease
Study Start Date : January 2012
Actual Primary Completion Date : August 2013
Actual Study Completion Date : August 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Rosuvastatin
Patients that receive rosuvastatin
Drug: Rosuvastatin
Patients will be started at 20 mg per day and then increased to 40 mg per day if not at target by six weeks
Other Name: Crestor

Primary Outcome Measures :
  1. LDL value [ Time Frame: three months ]
    LDL value recorded three months after study entry

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 30 and above
  • Rankin score of ≤ 3
  • Patient has a fixed telephone number and is available for follow-up
  • African American
  • Diagnosis of ischemic stroke or TIA in past 12 months

Exclusion Criteria:

  • Liver enzyme abnormalities (ALT or AST >2x ULN)
  • Known muscle disorder or CK > 5x ULN
  • Alcoholism or substance abuse
  • Stroke due to dissection or hypercoagulable state
  • Moderate to severe dementia (MMSE <20)
  • On hemodialysis
  • No fixed home address

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01975194

Layout table for location information
United States, Michigan
Detroit Medical Center
Detroit, Michigan, United States, 48201
Sponsors and Collaborators
Wayne State University
Layout table for investigator information
Principal Investigator: Seemant Chaturvedi, MD Wayne State University

Layout table for additonal information
Responsible Party: Seemant Chaturvedi, Professor of Neurology, Wayne State University Identifier: NCT01975194    
Other Study ID Numbers: 0481540
First Posted: November 3, 2013    Key Record Dates
Last Update Posted: November 5, 2013
Last Verified: November 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Ischemic Attack, Transient
Cerebrovascular Disorders
Brain Ischemia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors